Patents by Inventor Osam Mazda
Osam Mazda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124842Abstract: Provided is a method of preparing a somatic cell including converting a differentiated somatic cell of a mammal to other somatic cell by culturing the differentiated somatic cell in a medium for inducing differentiation of the somatic cell other than the differentiated somatic cell in the presence of a TGF-? pathway inhibitor.Type: ApplicationFiled: December 22, 2023Publication date: April 18, 2024Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Kenta YAMAMOTO, Tsunao KISHIDA, Yoshihiro SOWA, Toshiro YAMAMOTO, Osam MAZDA
-
Publication number: 20240084258Abstract: The present invention aims to provide a brown adipocyte and a generation method thereof, a transplantation material containing a brown adipocyte, a prophylactic agent or therapeutic agent containing a brown adipocyte for various diseases and conditions, and use thereof. Provided is a method for generating a brown adipocyte, including converting a differentiated somatic cell of a mammal to a brown adipocyte by culturing the somatic cell in a medium in the presence of at least one kind of a compound selected from the group consisting of (1) a TGF?/SMAD pathway inhibitor, (2) a casein kinase 1 inhibitor, (3) a cAMP inducer and (4) a MEK/ERK pathway inhibitor.Type: ApplicationFiled: November 22, 2023Publication date: March 14, 2024Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Kenta YAMAMOTO, Tsunao Kishida, Toshiro Yamamoto, Osam Mazda
-
Patent number: 11851681Abstract: Provided is a method of preparing a somatic cell including converting a differentiated somatic cell of a mammal to other somatic cell by culturing the differentiated somatic cell in a medium for inducing differentiation of the somatic cell other than the differentiated somatic cell in the presence of a TGF-? pathway inhibitor.Type: GrantFiled: October 20, 2016Date of Patent: December 26, 2023Assignee: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Kenta Yamamoto, Tsunao Kishida, Yoshihiro Sowa, Toshiro Yamamoto, Osam Mazda
-
Publication number: 20220298486Abstract: The present invention aims to provide a method for preparing urothelial cells that can be applied to the treatments of urologic diseases, particularly, diseases caused by urothelial cell damage, diseases caused by loss of urothelial cells and dysfunction, and the like, urothelial cells prepared by said method, and a medium for inducing (generating) urothelial cells. Urothelial cells prepared by a method for inducing a urothelial cell, including a step of introducing at least one member selected from the group consisting of FOXA1 (Forkhead box A1) gene or an expression product thereof, TP63 (tumor protein P63) gene or an expression product thereof, MYCL (L-Myc) gene or an expression product thereof, and KLF4 (Kruppel-like factor 4) gene or an expression product thereof to a mammalian somatic cell as an exogeneous factor can be applied to the treatment of urologic diseases.Type: ApplicationFiled: August 28, 2020Publication date: September 22, 2022Inventors: Yuta Inoue, Osam Mazda, Tsunao Kishida, Osamu Ukimura, Makoto Seki
-
Patent number: 11242541Abstract: Provided is a method for inducing a skeletal muscle cell including a step of introducing MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof into a somatic cell of a mammal.Type: GrantFiled: December 28, 2017Date of Patent: February 8, 2022Assignee: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Junko Wakao, Tsunao Kishida, Tatsuro Tajiri, Osam Mazda
-
Patent number: 11174464Abstract: An object of the present invention is to provide a method for preparing osteoblasts that are applicable, without causing risk of canceration, to bone defect repair or to the treatment of bone resorption, fracture, osteoporosis, or the like. To solve this problem, the present invention provides a method for preparing osteoblasts, the method comprising culturing mammal differentiated somatic cells in a medium in the presence of at least one compound selected from the group consisting of (1) statin compounds, (2) casein kinase 1 inhibitors, (3) cAMP inducers, and (4) histone methyltransferase inhibitors, to convert the somatic cells into osteoblasts.Type: GrantFiled: April 17, 2015Date of Patent: November 16, 2021Assignee: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Kenta Yamamoto, Tsunao Kishida, Toshiro Yamamoto, Osam Mazda
-
Patent number: 11021685Abstract: An object of the present invention is to provide a method for generating an osteoblast that is applicable to repair of a bone defect due to various tumors, injuries, surgeries, etc. and to treatment for bone resorption typified by a periodontal disease, bone fracture, osteoporosis, etc., and that has a low risk of carcinogenesis. Provided as a means for achieving this object is a method for generating an osteoblast from a somatic cell of a mammal, the method comprising introducing Oct9 gene or an expression product thereof into the somatic cell.Type: GrantFiled: February 21, 2018Date of Patent: June 1, 2021Assignee: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Kenta Yamamoto, Tsunao Kishida, Toshiro Yamamoto, Osam Mazda
-
Publication number: 20200399603Abstract: This invention provides a method for preparing a brown adipocyte from a somatic cell of a mammal by introducing at least one brown adipocyte-related gene or expression product thereof and at least one reprogramming-related gene or expression product thereof into the somatic cell, the brown adipocyte-related gene being at least one member selected from the group consisting of PRDM16(P) and C/EBP?(C), the reprogramming-related gene being at least one member selected from the group consisting of Myc family genes (c-Myc(M), N-Myc, L-Myc(L), S-Myc, and B-Myc), GLIS family genes (GLIS1 (G), GLIS 2, and GLIS 3), Klf family genes (KLF1, KLF2, KLF3, KLF4(K), KLF5, KLF6, KLF7, KLF8, KLF9, KLF10, KLF11, KLF12, KLF13, KLF14, KLF15, KLF16, and KLF17), Oct family genes, Sox family genes, and Lin-28.Type: ApplicationFiled: September 2, 2020Publication date: December 24, 2020Applicant: Kyoto Prefectural Public University CorporationInventors: Tsunao Kishida, Osam Mazda
-
Patent number: 10675382Abstract: The present invention addresses the problem of providing a method for obtaining Schwann cells directly (by direct reprogramming) without passing through pluripotent stem cells, such as ES cells or iPS cells. As a means for solving this problem, the present invention provides a method for preparing Schwann cells that includes a step of introducing into somatic cells of a mammal at least one gene selected from the group consisting of SOX10 genes and KROX20 genes, or an expression product thereof.Type: GrantFiled: September 11, 2015Date of Patent: June 9, 2020Assignee: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Yoshihiro Sowa, Tsunao Kishida, Osam Mazda
-
Publication number: 20200163854Abstract: This invention provides a life-extending agent comprising at least one member selected from the group consisting of D-proline, D-hydroxyproline, and D-aspartic acid.Type: ApplicationFiled: August 2, 2018Publication date: May 28, 2020Applicants: KYOTO UNIVERSITY, KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, NATIONAL UNIVERSITY CORPORATION KYOTO INSTITUTE OF TECHNOLOGYInventors: Kenji SATO, Osam MAZDA, Tsunao KISHIDA, Yoshihiro INOUE
-
Patent number: 10557120Abstract: The present invention relates to: a method of preparing an osteoblast from a somatic cell of a mammal, the method including introducing a bone-related gene or an expression product thereof and a reprogramming-related gene or an expression product thereof, or introducing a reprogramming-related gene or an expression product thereof independently into the somatic cell, the bone-related gene including at least one kind selected from the group consisting of Runx2 (R), Osterix (O), and Dlx5 (D), the reprogramming-related gene including at least one kind selected from the group consisting of Oct family, c-Myc (M), L-Myc (L), Klf family, Lin-28, and Sox2; and an osteoblast prepared by the method.Type: GrantFiled: July 24, 2014Date of Patent: February 11, 2020Assignee: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Kenta Yamamoto, Tsunao Kishida, Toshiro Yamamoto, Osam Mazda
-
Publication number: 20190338306Abstract: Provided is a method for inducing a skeletal muscle cell including a step of introducing MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof into a somatic cell of a mammal.Type: ApplicationFiled: December 28, 2017Publication date: November 7, 2019Inventors: Junko Wakao, Tsunao Kishida, Tatsuro Taijiri, Osam Mazda
-
Publication number: 20190024054Abstract: Provided is a method of preparing a somatic cell including converting a differentiated somatic cell of a mammal to other somatic cell by culturing the differentiated somatic cell in a medium for inducing differentiation of the somatic cell other than the differentiated somatic cell in the presence of a TGF-? pathway inhibitor.Type: ApplicationFiled: October 20, 2016Publication date: January 24, 2019Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Kenta YAMAMOTO, Tsunao KISHIDA, Yoshihiro SOWA, Toshiro YAMAMOTO, Osam MAZDA
-
Publication number: 20180355319Abstract: The present invention aims to provide a brown adipocyte and a generation method thereof, a transplantation material containing a brown adipocyte, a prophylactic agent or therapeutic agent containing a brown adipocyte for various diseases and conditions, and use thereof. Provided is a method for generating a brown adipocyte, including converting a differentiated somatic cell of a mammal to a brown adipocyte by culturing the somatic cell in a medium in the presence of at least one kind of a compound selected from the group consisting of (1) a TGF?/SMAD pathway inhibitor, (2) a casein kinase 1 inhibitor, (3) a cAMP inducer and (4) a MEK/ERK pathway inhibitor.Type: ApplicationFiled: August 8, 2016Publication date: December 13, 2018Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Kenta YAMAMOTO, Tsunao KISHIDA, Toshiro YAMAMOTO, Osam MAZDA
-
Publication number: 20180195043Abstract: An object of the present invention is to provide a method for generating an osteoblast that is applicable to repair of a bone defect due to various tumors, injuries, surgeries, etc. and to treatment for bone resorption typified by a periodontal disease, bone fracture, osteoporosis, etc., and that has a low risk of carcinogenesis. Provided as a means for achieving this object is a method for generating an osteoblast from a somatic cell of a mammal, the method comprising introducing Oct9 gene or an expression product thereof into the somatic cell.Type: ApplicationFiled: February 21, 2018Publication date: July 12, 2018Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Kenta YAMAMOTO, Tsunao KISHIDA, Toshiro YAMAMOTO, Osam MAZDA
-
Publication number: 20170252484Abstract: The present invention addresses the problem of providing a method for obtaining Schwann cells directly (by direct reprogramming) without passing through pluripotent stem cells, such as ES cells or iPS cells. As a means for solving this problem, the present invention provides a method for preparing Schwann cells that includes a step of introducing into somatic cells of a mammal at least one gene selected from the group consisting of SOX10 genes and KROX20 genes, or an expression product thereof.Type: ApplicationFiled: September 11, 2015Publication date: September 7, 2017Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Yoshihiro SOWA, Tsunao KISHIDA, Osam MAZDA
-
Publication number: 20170037374Abstract: An object of the present invention is to provide a method for preparing osteoblasts that are applicable, without causing risk of canceration, to bone defect repair or to the treatment of bone resorption, fracture, osteoporosis, or the like. To solve this problem, the present invention provides a method for preparing osteoblasts, the method comprising culturing mammal differentiated somatic cells in a medium in the presence of at least one compound selected from the group consisting of (1) statin compounds, (2) casein kinase 1 inhibitors, (3) cAMP inducers, and (4) histone methyltransferase inhibitors, to convert the somatic cells into osteoblasts.Type: ApplicationFiled: April 17, 2015Publication date: February 9, 2017Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Kenta YAMAMOTO, Tsunao KISHIDA, Toshiro YAMAMOTO, Osam MAZDA
-
Publication number: 20160160180Abstract: The present invention relates to: a method of preparing an osteoblast from a somatic cell of a mammal, the method including introducing a bone-related gene or an expression product thereof and a reprogramming-related gene or an expression product thereof, or introducing a reprogramming-related gene or an expression product thereof independently into the somatic cell, the bone-related gene including at least one kind selected from the group consisting of Runx2 (R), Osterix (O), and Dlx5 (D), the reprogramming-related gene including at least one kind selected from the group consisting of Oct family, c-Myc (M), L-Myc (L), Klf family, Lin-28, and Sox2; and an osteoblast prepared by the method.Type: ApplicationFiled: July 24, 2014Publication date: June 9, 2016Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Kenta YAMAMOTO, Tsunao KISHIDA, Toshiro YAMAMOTO, Osam MAZDA
-
Publication number: 20150166958Abstract: This invention provides a method for preparing a brown adipocyte from a somatic cell of a mammal by introducing at least one brown adipocyte-related gene or expression product thereof and at least one reprogramming-related gene or expression product thereof into the somatic cell, the brown adipocyte-related gene being at least one member selected from the group consisting of PRDM16(P) and C/EBP?(C), the reprogramming-related gene being at least one member selected from the group consisting of Myc family genes (c-Myc(M), N-Myc, L-Myc(L), S-Myc, and B-Myc), GLIS family genes (GLIS1 (G), GLIS 2, and GLIS 3), Klf family genes (KLF1, KLF2, KLF3, KLF4(K), KLF5, KLF6, KLF7, KLF8, KLF9, KLF10, KLF11, KLF12, KLF13, KLF14, KLF15, KLF16, and KLF17), Oct family genes, Sox family genes, and Lin-28.Type: ApplicationFiled: July 12, 2013Publication date: June 18, 2015Applicant: Kyoto Prefectural Public University CorporationInventors: Tsunao Kishida, Osam Mazda
-
Publication number: 20130052170Abstract: Disclosed is a method for producing a grafting material that comprises a step in which a grafting material that expresses a secreted protein is obtained by differentiating iPS cells that have had a gene for a secreted protein introduced therein.Type: ApplicationFiled: April 28, 2011Publication date: February 28, 2013Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Osam Mazda, Tsunao Kishida